The role of cytochrome P450 3A4 in alfentanil clearance: Implications for interindividual variability in disposition and perioperative drug interactions

Anesthesiology

Volumn 87, Issue 1, 1997, Pages 36-50

  Kharasch, Evan D ^a   Russell, Michael ^b   Mautz, Douglas ^b   Thummel, Kenneth E ^b   Kunze, Kent L ^b   Andrew Bowdle, T ^b   Cox, Kathy ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

Analgesics, opioid: alfentanil, fentanyl, sufentanil, remifentanil; Anesthetics, intravenous: alfentanil, fentanyl, midazolam, remifentanil, sufentanil; Enzymes, cytochrome P450 3A4; Interactions, drug; Pharmacokinetics: aging; computer simulations; context sensitive half time; variability; women; Rifampin; Troleandomycin

Indexed keywords

ALFENTANIL; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; MIDAZOLAM; RIFAMPICIN; TROLEANDOMYCIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISPOSITION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME METABOLISM; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALFENTANIL; ANESTHETICS, INTRAVENOUS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MALE; MIXED FUNCTION OXYGENASES;

EID: 0030868233     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199707000-00006     Document Type: Article

References (59)

1. Ausems ME, Stanski DR, Hug CC: An evaluation of the accuracy of pharmacokinetic data for the computer assisted infusion of alfentanil. Br J Anaesth 1985; 57:1217-25
2. Maitre PO, Ausems ME, Vozeh S, Stanski DR: Evaluating the accuracy of using population pharmacokinetic data to predict plasma concentrations of alfentanil. ANESTHESIOLOGY 1988; 68:59-67
3. Jenstrup M, Fruergard K, Nielsen J, Moller A-M, Wiberg-Jorgensen F: Alfentanil infusion in total intravenous anaesthesia (TIVA). Population pharmacokinetics fails to predict plasma concentration of alfentanil. Acta Anaesthesiol Scand 1992; 36:846-7
4. Barvais L, Contraine F, D'Hollander A, Coussaert E: Predictive accuracy of continuous alfentanil infusion in volunteers: Variability of different pharmacokinetic sets. Anesth Analg 1993; 77:801-10
5. Maitre PO, Vozeh S, Heykants J, Thomson DA, Stanski DR: Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. ANESTHESIOLOGY 1987; 66:13-16
6. Wood M: Variability of human drug response. ANESTHESIOLOGY 1989; 71:631-4
7. Bovill JG, Sebel PS, Blackburn CL, Heykants J: The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. ANESTHESIOLOGY 1982; 57:439-43
8. Helmers H, Van Peer A, Woestenborghs R, Noorduin H, Heykants J: Alfentanil kinetics in the elderly. Clin Pharmacol Ther 1984; 36:239-43
9. Shafer A, Sung ML, White PF: Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. Anesth Analg 1986; 65:1021-8
10. Bartkowski RR, McDonnell TE: Prolonged alfentanil effect following erythromycin. ANESTHESIOLOGY 1990; 73:566-8
11. Coldberg ME, Torjman M, Bartkowski RR, Mora CT, Boerner T, Seltzer JL: Time-course of respiratory depression after an alfentanil infusion-based anesthetic. Anesth Analg 1992; 75:965-71
12. Jarvis DA, Duncan SR, Segal IS. Maze M: Ventilatory effects of clonidine alone and in the presence of alfentanil, in human volunteers. ANESTHESIOLOGY 1992; 76:899-905
13. Lemmens HJM, Burm AGL, Hennis PJ, Gladines MPPR, Bovill JG: Influence of age on the pharmacokinetics of alfentanil - gender dependence, Clin Pharmacokinet 1990; 19:416-22
14. Rubin A, Cox C: Sex, age and alfentanil pharmacokinetics. Clin Pharmacokinet 1991; 21:81-2
15. Scolt JC, Sianski DR: Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240:159-66
16. Lavrijsen KLM, Van Houdt JMG, Van Dyck DMJ. Hendrickx JJJM, Woestenborghs RJH, Lauwers W, Meuldermans WEG, Heykants JJP: Is the metabolism of alfentanil subject to debrisoquine polymorphism? ANESTHESIOLOGY 1988; 69:535-40
17. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED: Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 1995; 23:490-6
18. Kharasch ED, Thummel K: Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance? Anesth Analg 1993; 76:1033-9
19. Yun C-H, Wood M, Wood AJJ, Guengerich FP: Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P450 3A4. ANESTHESIOLOGY 1992; 77:467-74
20. Wrighton SA, Stevens JC: The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22:1-21
21. Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Hartwell P, Raisys V, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL: Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994; 271:549-56
22. Bailey DG, Arnold JMO, Spence JD: Grapefruit juice and drugs: How significant is the interaction? Clin Pharmacokinet 1994; 26:91-8
23. Mautz DM, Labroo RB, Kharasch ED: Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectroimetry. J Chromatogr B 1994; 658:149-53
24. Labroo RB, Kharasch ED: Gas chromatographic-mass spectrometric analysis of alfentanil metabolites. Application to human liver microsomal alfentanil biotransformation. J Chromatogr B 1994; 660:85-94
25. Paine MF, Shell DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE: First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60:14-24
26. Lykkesfeldt J, Loft S, Poulsen HE: Simultaneous determination of urinary free Cortisol and 6β-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J Chromatogr B 1994; 660:23-9
27. Berman M, Shahn E, Weiss MF: The routine fitting of kinetic data to models: A mathematical formalism for digital computers. Biophys J 1962; 2:275-87
28. Pessayre D, Larrey D, Vitaux J, Breil P, Belghiti J, Benhamou JP: Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem Pharmacol 1982; 31:1699-704
29. Newton DJ, Wang RW, Lu AYH: Cytochrome P450 inhibitors. Evaluations of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23:154-8
30. Schellens JHM, van der Wart JHF, Brugman M, Breimer DD: Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther 1989; 249:638-45
31. Periti P, Mazzei T, Mini E, Novelli A: Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23:106-31
32. Li AP, Kaminski DL, Rasmussen A: Substrates of human hepatic cytochronic P450 3A4. Toxicology 1995; 104:1-8
33. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P: The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989; 28:373-87
34. Venkatesan K: Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992; 22:47-65
35. Hebert MF, Roberts JP, Prueksaritanot T, Benet LZ: Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52:453-7
36. Backman JT, Olkkola KT, Neuvonen PJ: Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996; 59:7-13
37. Bachmann KA, Jauregui L: Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica 1993; 23:307-15
38. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 caucasians. J Pharmacol Exp Ther 1994; 270:414-23
39. Harris RZ, Benet LZ, Schwartz JB: Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50:222-39
40. Horsmans Y, Desager JP, Harvengt C: Absence of CYP3A genetic polymorphismassessed by urinary excretion by 6 -hydroxycortisol in 102 healthy subjects on rifampicin. Pharmacol Toxicol 1992; 71:258-61
41. Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, Fishman K, Guzelian PS, Voorhees JJ: Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992; 52:265-73
42. Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Watlington CO, Wright JT, Guzelian PS: Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 1992; 51:18-23
43. Kinirons MT, Oshea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, Wilkinson GR, Wood AJJ: Absence of correlations among 3 putative invivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993; 54:621-9
44. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez J-F: Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone phamacokinetics. Biochem Pharmacol 1994; 47:1503-8
45. Berthou F, Goasduff T, Lucas D, Dreano Y, Le Bot M-H, Menez J-F: Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics 1995; 5:72-9
46. Shater SL, Varvel JR: Pharmacokinetics, pharmacodynamics, and rational opioid selection. ANESTHESIOLOGY 1991; 74:53-65
47. Hughes MA, Glass PSA., Jacobs JR: Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. ANESTHESIOLOGY 1992; 76:334-41
48. Kapila A, Glass PSA, Jacobs JR, Muir KT, Hermann DJ, Shiraishi M, Howell S, Smith RL: Measured context-sensitive half-times of remifentanil and alfentanil. ANESTHESIOLOGY 1995; 83:968-75
49. Stanski DR, Shafer SL: Quantifying anesthetic drug interaetion. Implicalions for drug dosing. ANESTHESIOLOGY 1995; 83:1-5
50. Egan TD, Lemmens HJM, Fiset P, Hermann DJ, Muir KT, Stanski DR, Shafer SL: The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ANESTHESIOLOGY 1993; 79:881-92
51. Hung OR, Whynot SC Varvel JR, Shafer SL, Mezei M: Pharmacokinetics of inhaled liposome-encapsulated fentanyl. ANESTHESIOLOGY 1995; 83:277-84
52. Wrighton SA, Ring BJ, Watkins PB, Vandenbranden M: Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989; 36:97-105
53. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH: Cytochrome P-450 isoenzymes, epoxide hydrolase and glutathione transferase in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253:387-97
54. Guengerich FP, Turvy CG: Comparison of levels of several human microsomal cytochrome-P-450 enzymes and epoxide hy drolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991; 256:1189-94
55. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ: Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986; 261:5051-60
56. Wrighton SA, Brian WR, Sari M-A, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M: Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38:207-13
57. Kassai A, Toth G, Eichelbaum M, Klotz U: No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. Clin Pharmacokin 1988; 15:319-25
58. Hunt CM, Westerkam WR, Stave GM: Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44:275-83
59. Hunt CM, Westerkam WR, Stave GM, Wilson JAP: Hepatic cytochrome P-4503A (CYP3A) in the elderly. Mech Ageing Dev 1992; 64:189-99